Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-cash Items: 2019-2024

Historic Non-cash Items for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $10.3 million.

  • BridgeBio Pharma's Non-cash Items fell 83.49% to $10.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $10.9 million, marking a year-over-year decrease of 83.49%. This contributed to the annual value of $10.3 million for FY2024, which is 94.25% down from last year.
  • Latest data reveals that BridgeBio Pharma reported Non-cash Items of $10.3 million as of FY2024, which was down 94.25% from $178.6 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Non-cash Items ranged from a high of $178.6 million in FY2023 and a low of $1.7 million during FY2020.
  • For the 3-year period, BridgeBio Pharma's Non-cash Items averaged around $65.3 million, with its median value being $10.3 million (2024).
  • As far as peak fluctuations go, BridgeBio Pharma's Non-cash Items spiked by 2,418.35% in 2023, and later crashed by 94.25% in 2024.
  • Yearly analysis of 5 years shows BridgeBio Pharma's Non-cash Items stood at $1.7 million in 2020, then surged by 189.85% to $5.0 million in 2021, then skyrocketed by 40.89% to $7.1 million in 2022, then surged by 2,418.35% to $178.6 million in 2023, then plummeted by 94.25% to $10.3 million in 2024.